ACS Pharmacology & Translational Science · 2022 · 12 citations · 23 references
MedicineOncologyPharmacologyBiophotonicsCancer PharmacologyDrug DeliveryPhotochemistryPhotodynamic TherapyCancer Photodynamic TherapyLight DosimetryPhotosensitizersPhotosensitizing CompoundsPhototoxicityPhototoxicity ReductionSolubilityTumor Regression Assessment
Photodynamic therapy (PDT), performed with low-fluence rates, can improve antitumor responses and prevent adverse effects. However, photosensitizers (PSs) for low-fluence PDT treatment are rarely reported. Herein, we exploited an amphiphilic chlorin-based PS, named DYSP-C34, which has a variety of beneficial biological properties, such as improved water solubility, better cellular permeability, specific localization and enhanced phototoxicity under low light dose irradiation. In addition, DYSP-C34 could effectively accumulate in a mouse subcutaneous xenograft tumor and exhibit substantial tumor regression after irradiation with an extremely low light fluence (6 J/cm2). Meanwhile, the excellent phototoxicity could stimulate the host immune system and lead to a strong inhibition of tumor growth synergistically. These results indicated the potential value of DYSP-C34 as a chlorin-type PS for low-fluence PDT application.
23
Hematoporphyrin Derivative and Laser Photoradiation in the Treatment of Lung Cancer
Yoshihiro Hayata, Harubumi Kato, Chimori Konaka et al. · CHEST Journal · 1982 · 522 citations
Medicine, Oncology, Pharmacology +14
<i>In Situ</i> Dendritic Cell Vaccine for Effective Cancer Immunotherapy
Weijing Yang, Guizhi Zhu, Sheng Wang et al. · ACS Nano · 2019 · 236 citations
Pharmacy, Immunology, Oncology +17
John Trachtenberg, Robert Weersink, Sean M. Davidson et al. · British Journal of Urology · 2008 · 167 citations